Solid Biosciences Ownership
| SLDB Stock | USD 5.86 0.45 8.32% |
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 41 M | Current Value 41 M | Avarage Shares Outstanding 9.8 M | Quarterly Volatility 11.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Solid |
Solid Stock Ownership Analysis
About 90.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Solid Biosciences LLC recorded a loss per share of 3.04. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 28th of October 2022. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people. To find out more about Solid Biosciences LLC contact Alexander Cumbo at 617 337 4680 or learn more at https://www.solidbio.com.Besides selling stocks to institutional investors, Solid Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Solid Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Solid Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Solid Biosciences Quarterly Liabilities And Stockholders Equity |
|
Solid Biosciences Insider Trades History
Less than 1% of Solid Biosciences LLC are currently held by insiders. Unlike Solid Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Solid Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Solid Biosciences' insider trades
Solid Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Solid Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Solid Biosciences LLC backward and forwards among themselves. Solid Biosciences' institutional investor refers to the entity that pools money to purchase Solid Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 920.5 K | Hhg Plc | 2024-06-30 | 753 K | Geode Capital Management, Llc | 2024-09-30 | 504.9 K | Monashee Investment Management Llc | 2024-09-30 | 485 K | Silverarc Capital Management, Llc | 2024-06-30 | 473 K | Point72 Asset Management, L.p. | 2024-09-30 | 443 K | Walleye Trading Advisors, Llc | 2024-06-30 | 412 K | State Street Corp | 2024-06-30 | 404.4 K | Alyeska Investment Group, L.p. | 2024-09-30 | 346.4 K | Perceptive Advisors Llc | 2024-09-30 | 6.9 M | Ra Capital Management, Llc | 2024-09-30 | 4.3 M |
Solid Biosciences LLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Solid Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Solid Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Solid Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Solid Biosciences Outstanding Bonds
Solid Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Solid Biosciences LLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Solid bonds can be classified according to their maturity, which is the date when Solid Biosciences LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Solid Biosciences Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 12th of June 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.